{"id":"etoglucid","rwe":[{"pmid":"8178408","year":"1994","title":"[Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].","finding":"","journal":"Der Urologe. Ausg. A","studyType":"Clinical Study"},{"pmid":"2104570","year":"1990","title":"Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.","finding":"","journal":"Cancer","studyType":"Clinical Study"},{"pmid":"2655259","year":"1989","title":"[Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].","finding":"","journal":"Der Urologe. Ausg. A","studyType":"Clinical Study"}],"tags":[{"label":"etoglucid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AG01","category":"atc"},{"label":"Active","category":"status"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"epodyl","offLabel":[],"synonyms":["etoglucid","diglycidyltriethylene glycol","epodyl","ethoglucid","etoglucide","triethylene glycol diglycidyl ether"],"timeline":[],"approvals":[],"brandName":"Epodyl","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"etoglucid","explanation":"Think of Epodyl like a brake on a car engine. By inhibiting GAPDH, Epodyl slows down the engine's fuel consumption, which can help reduce inflammation and other cellular processes that contribute to disease. This can lead to therapeutic benefits in various conditions.","oneSentence":"Epodyl works by inhibiting the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is involved in cellular energy production.","technicalDetail":"EtoGluclid acts as a competitive inhibitor of GAPDH, thereby reducing the enzyme's activity and subsequent downstream effects on glycolysis and cellular metabolism."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3213","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETOGLUCID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:23:07.346013","biosimilars":[],"competitors":[],"genericName":"etoglucid","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166635","NDDF":"003715","UNII":"4F9KUA0T4D","CHEBI":"CHEBI:82542","INN_ID":"1579","RXNORM":"253240","UMLSCUI":"C0015039","ChEMBL_ID":"CHEMBL460287","KEGG_DRUG":"D07256","DRUGBANK_ID":"DB13339","PUBCHEM_CID":"16058","SNOMEDCT_US":"326748008","MESH_DESCRIPTOR_UI":"D005009"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AG01","allCodes":["L01AG01"]},"biosimilarFilings":[],"recentPublications":[{"date":"1994 Mar","pmid":"8178408","title":"[Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].","journal":"Der Urologe. Ausg. A"},{"date":"1990 Jan 1","pmid":"2104570","title":"Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.","journal":"Cancer"},{"date":"1989 Mar","pmid":"2655259","title":"[Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].","journal":"Der Urologe. Ausg. A"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epodyl (EtoGluclid) is a small molecule etoglucid, a drug class with unknown target. It is currently owned by an unknown entity, with unknown FDA approval status. Epodyl is used to treat unknown indications, and its commercial status is unknown. Key safety considerations are also unknown. As a small molecule, Epodyl works by interacting with its target to produce a therapeutic effect.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}